ARA-290: reported timelines in the literature

ARA-290 (also written ARA 290) is a synthetic peptide described in the clinical literature as a non-hematopoietic erythropoietin analogue and as a member of a new class of compound [2][3]. The evidence block for this page does not give a sequence, molecular formula, or molecular weight for ARA-290, so none is stated here. The work summarised below centres on the innate repair receptor, a receptor complex that ARA-290 is reported to interact with briefly, producing anti-apoptotic and anti-inflammatory activity across a range of cells, tissues and organs [2].

Reported timelines in the literature are study-level, not pharmacological. The shortest reported exposure in the evidence block is a single dose in healthy volunteers, with a cognitive and neural endpoint assessed 7 days after administration [4]. The longest reported daily dosing schedule is 12 weeks, given subcutaneously at 4 mg per day in a phase II trial in diabetic macular oedema [1]. Between those two extremes sit a 28-day daily subcutaneous schedule in sarcoidosis with small fiber neuropathy symptoms [2] and a study in prediabetes and drug-naive type 2 diabetes that evaluates effects on blood glucose, insulin secretion, insulin sensitivity and serum inflammatory markers [3].

Research Studies

ARA-290 and diabetic macular oedema in type 1 or type 2 diabetes

The ARA 290-DMO study is described as a prospective, open label, interventional, single centre, investigator led, phase II trial examining the effect of ARA 290 on diabetic macular oedema in patients with type 1 or type 2 diabetes [1]. The primary objective was to determine whether ARA 290, administered at a daily dose of 4 mg subcutaneously for 12 weeks, would have a beneficial effect on the mean change in best corrected visual acuity (BCVA) from baseline to week 12 [1]. The reported timeline for this study is therefore a 12-week daily dosing period with the primary endpoint read at week 12 [1].

ARA-290 and corneal nerve fiber density and neuropathic symptoms in sarcoidosis

In this study, subjects with sarcoidosis and symptoms of small fiber neuropathy were to be administered ARA 290 or placebo by subcutaneous injection daily for 28 days [2]. The stated purpose was to determine whether ARA 290 is effective in the treatment of the neuropathic symptoms of sarcoidosis, and safety was monitored alongside the symptom assessments [2]. The reported timeline is a 28-day daily subcutaneous course, with ARA 290 compared against placebo [2].

ARA-290 and glycaemic and inflammatory parameters in prediabetes and type 2 diabetes

This study was designed to determine whether ARA 290, described as a non-hematopoietic erythropoietin analogue, exerts beneficial effects on blood glucose levels and insulin secretion in persons with prediabetes (impaired glucose tolerance or impaired fasting glucose) or drug-naive type 2 diabetes [3]. It also evaluates effects on insulin sensitivity and serum levels of inflammatory agents such as cytokines, with safety monitored through haematology, kidney and liver function parameters and lipid levels [3]. The evidence block does not state a dosing duration for this study, so no timeline is given here beyond the parameters listed.

ARA-290 and cognitive and neural processing of emotions in healthy volunteers

This study examined the effects of ARA 290 on the cognitive and neural processing of emotions in healthy volunteers, in an attempt to replicate previous findings with a single dose of erythropoietin [4]. The hypothesis was that a single dose of ARA 290 would lead to a positive shift in information processing compared with placebo, assessed 7 days post-administration [4]. The reported timeline is therefore a single dose with a 7-day post-dose assessment point [4]. The rationale given is that ARA 290 is a peptide that does not have the effects of erythropoietin on blood cells but may still act on brain function [4].

ARA-290 and regenerative peptide applications in tissue repair and chronic pain

A narrative review summarises current evidence on regenerative peptides relevant to chronic pain management, including collagen peptides, BPC-157, TB-4, TB-500 and GHK-Cu [5]. ARA-290 is not named in the portion of that review available in the evidence block, and no timeline for ARA-290 is reported there [5]. The review is included here as context for the broader peptide class and is not the basis of any timeline claim on this page.

Reported dosing schedules across studies

The table below compares the dosing schedules and assessment points that the evidence block states for each study. Where a value is not given in the evidence, the cell is left blank rather than estimated.

ARA-290 and the innate repair receptor

The mechanism named in the evidence block is a brief interaction between ARA 290 and the innate repair receptor, reported to result in anti-apoptotic and anti-inflammatory activities in a range of cells, tissues and organs, activating repair mechanisms and accelerating healing, including nerve damage that can be associated with sarcoidosis [2]. This mechanism statement is given as the rationale for the sarcoidosis study and is not accompanied in the evidence block by a timeline of receptor engagement or downstream signalling [2].

ARA-290 and the erythropoietin comparison

ARA 290 is described as an erythropoietin analogue that is non-hematopoietic [3], and separately as a peptide that does not have the effects of erythropoietin on blood cells but may still affect brain function [4]. The cognitive study notes that repeated administration of erythropoietin may cause serious side-effects such as thrombosis, which limits its usefulness as an antidepressant, and that ARA 290 was studied in an attempt to replicate prior erythropoietin findings without that limitation [4]. No timeline for any haematological parameter is given in the evidence block for ARA 290 itself.

ARA-290 and safety monitoring parameters

Safety monitoring is described in the prediabetes and type 2 diabetes study through haematology, kidney and liver function parameters and lipid levels [3], and in the sarcoidosis study through monitoring of treatment safety alongside symptom assessment [2]. The evidence block does not report the timing of those safety assessments, so no schedule is given here.

ARA-290 and study design characteristics

The diabetic macular oedema study is described as prospective, open label, interventional, single centre, investigator led and phase II [1]. The sarcoidosis study is described as administering ARA 290 or placebo [2]. The cognitive study is described as comparing a single dose of ARA 290 with placebo in healthy volunteers [4]. The prediabetes and type 2 diabetes study is described as evaluating effects on glucose, insulin and inflammatory parameters [3]. These design features are reported as stated and are not extrapolated to other populations.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page is medical advice. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] The Use of ARA290 for the Treatment of Diabetic Macular Oedema
• [2] Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
• [3] ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
• [4] Cognitive and Neural Effects of ARA290
• [5] Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.